Menu
image description

Tag: Janssen

STELARA® Shows Positive Results

STELARA® (Ustekinumab) Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial   60 percent of patients receiving STELARA® showed significant reductions in lupus disease activity vs. 31 percent of patients receiving placebo STELARA® showed significant improvements in various disease measures compared with placebo, including musculoskeletal, mucocutaneous, immunological markers and flares Janssen […] Read More

Lupus Research Alliance Prompted Stelara® Study for Lupus

Lupus Research Alliance welcomes compelling new data, presented at the American College of Rheumatology (ACR) annual meeting that demonstrated significant benefit for lupus patients treated with Stelara® (ustekinumab), a prescription medicine from the Janssen Pharmaceutical Companies. Stelara® is not approved for the treatment of lupus, but is approved by the FDA for certain autoimmune diseases. Through its drug repurposing program, the Lupus Research Alliance first identified Stelara® as a potential treatment for lupus and encouraged Janssen to pursue testing for this use. Read More

because the Lupus Research Alliance board of directors funds all administrative and fundraising costs